Safety Study of a Radiolabeled Antibody (7E11) in Patients With Progressive Hormone Refractory Prostate Cancer

NCT00441571 · clinicaltrials.gov ↗

PHASE1

Phase

UNKNOWN

Status

30

Enrollment

INDUSTRY

Sponsor class

Conditions

Metastatic Prostate Cancer

Interventions

DRUG: 177Lu-CYT-500

Sponsor

Cytogen Corporation